{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-028023","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.682415+00:00","generated_at":"2026-05-15T11:56:48.618354+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Positive Phase 2 data: oral GLP-1 aleniglipron achieves up to 16.3% placebo-adjusted weight loss at 44 weeks","bullets":["Placebo-adjusted mean weight loss 16.3% at 180 mg and 16.0% at 240 mg (p<0.0001) at 44 weeks.","OLE study shows continued weight loss up to 16.2% at 56 weeks; no plateau observed.","Lower 2.5 mg starting dose improves tolerability; AE-related discontinuations 2-3.4% in interim OLE / body composition studies.","End-of-Phase 2 meeting with FDA scheduled Q2 2026; Phase 3 initiation on track for 2H 2026.","No drug-induced liver injury, no persistent liver enzyme elevations, no QTc prolongation across >625 participants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-028023","json":"https://secwatch.observer/filing/0001104659-26-028023.json","markdown":"https://secwatch.observer/filing/0001104659-26-028023.md","text":"https://secwatch.observer/filing/0001104659-26-028023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/0001104659-26-028023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/tm268880d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:56:48.618354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}